Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Contraceptives on Cervico-Vaginal Mucosa

NCT04814927
Conditions
Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions
Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Stress Hormones and IUDs

NCT03499379
Conditions
Contraception, Mood Change
Interventions
Mirena, Paraguard
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Menorrhagia
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
37
States / cities
Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more
Conditions
Contraception
Interventions
Kyleena
Drug
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Postpartum Contraception
Interventions
Levonorgestrel-releasing intrauterine system
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Conditions
Contraception
Interventions
LNG20, Mirena
Drug
Lead sponsor
Medicines360
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
1,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Conditions
Contraception
Interventions
Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
16 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portsmouth, Virginia
Conditions
Contraception
Interventions
Paragard, Mirena
Device · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Contraception, Postpartum Period
Interventions
LNG-IUS
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Portsmouth, Virginia
Conditions
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Completed Phase 3 Interventional Results available

Mirena Extension Trial

NCT02985541
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception

NCT01240811
Conditions
Genital Tract Mucosal Immunity, Genital Tract Microflora
Interventions
IUD placement, Levonorgestrel IUD, Copper T380A IUD
Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement

NCT01598662
Conditions
Contraception
Interventions
Mirena (levonorgestrel-releasing intrauterine system)
Device
Lead sponsor
University of Louisville
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LNG-IUS at 2 Weeks Postpartum

NCT02121067
Conditions
Contraception, Malposition of Intrauterine Contraceptive Device
Interventions
Levonorgestrel Intrauterine System (LNG-IUS)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Healthy
Interventions
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Not applicable Interventional Results available

Immediate Postplacental IUD Insertion

NCT02169869
Conditions
Contraception
Interventions
Mirena, Paragard
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois